DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Questions
Schema
Social Networks
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://www.nature.com/articles/nrd2742, but it redirected us to https://www.nature.com/articles/nrd2742. The analysis below is for the second page.

Title[redir]:
Knocking down barriers: advances in siRNA delivery | Nature Reviews Drug Discovery
Description:
RNA interference holds vast potential as a therapeutic strategy for both disease prevention and treatment, but its use has so far been hampered by a lack of safe and effective delivery techniques. In their Review, Anderson and colleagues discuss the challenges associated with small interfering RNA delivery and highlight promising novel synthetic delivery agents. In the 10 years that have passed since the Nobel prize-winning discovery of RNA interference (RNAi), billions of dollars have been invested in the therapeutic application of gene silencing in humans. Today, there are promising data from ongoing clinical trials for the treatment of age-related macular degeneration and respiratory syncytial virus. Despite these early successes, however, the widespread use of RNAi therapeutics for disease prevention and treatment requires the development of clinically suitable, safe and effective drug delivery vehicles. Here, we provide an update on the progress of RNAi therapeutics and highlight novel synthetic materials for the encapsulation and intracellular delivery of nucleic acids.

Matching Content Categories {📚}

Education
Science
Shopping

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We see no obvious way the site makes money.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Doi.org might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

pubmed, article, google, scholar, cas, sirna, nature, delivery, gene, rna, central, drug, silencing, rnai, interfering, vivo, usa, interference, proc, natl, acad, sci, therapeutic, med, small, cell, cells, targeting, target, access, cancer, res, sequencespecific, therapeutics, ther, content, journal, nucleic, effects, mice, biotech, research, cookies, mrna, technology, nonviral, cationic, activity, sirnas, short,

Topics {✒️}

permissions reprints peg-ylated magnetic-fluid-loaded liposomes nature portfolio privacy policy acid-labile β-thiopropionate linkage ph-responsive metal-organic framework advertising integrated cancer research lipid-mediated dna-transfection procedure rna-induced silencing complex nuclease-resistant double-stranded rna social media nobel prize-winning discovery research tool nanoparticle research low-ph-sensitive poly combinatorial library age-related macular degeneration author information authors anti-inflammatory host factor exploiting delivery system-induced rnai-mediated gene silencing rnai-mediated gene-targeting sirna-mediated gene silencing nature cell biol l-domain-dependent manner author correspondence vitamin a-coupled liposomes block copolymer/sirna polyplexes target-independent angiogenesis suppression sequence-specific gene silencing small interfering rnas polyelectrolyte complex micelles position-specific chemical modification large library bcr-abl1+ leukemia cells sequence-specific potent induction polyethylenimine-mediated sirna delivery vivo anti-hbv activity small interfering rna springerlink instant access live-animal bioluminescent imaging enhance sirna activity nucleic acid delivery permissions nature rev nature biotech nature mater short interfering rna nature med

Questions {❓}

SiRNA and the lung: research tool or therapeutic drug?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Knocking down barriers: advances in siRNA delivery
         description: RNA interference holds vast potential as a therapeutic strategy for both disease prevention and treatment, but its use has so far been hampered by a lack of safe and effective delivery techniques. In their Review, Anderson and colleagues discuss the challenges associated with small interfering RNA delivery and highlight promising novel synthetic delivery agents. In the 10 years that have passed since the Nobel prize-winning discovery of RNA interference (RNAi), billions of dollars have been invested in the therapeutic application of gene silencing in humans. Today, there are promising data from ongoing clinical trials for the treatment of age-related macular degeneration and respiratory syncytial virus. Despite these early successes, however, the widespread use of RNAi therapeutics for disease prevention and treatment requires the development of clinically suitable, safe and effective drug delivery vehicles. Here, we provide an update on the progress of RNAi therapeutics and highlight novel synthetic materials for the encapsulation and intracellular delivery of nucleic acids.
         datePublished:
         dateModified:
         pageStart:129
         pageEnd:138
         sameAs:https://doi.org/10.1038/nrd2742
         keywords:
            Biomedicine
            general
            Pharmacology/Toxicology
            Biotechnology
            Medicinal Chemistry
            Molecular Medicine
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrd2742/MediaObjects/41573_2009_Article_BFnrd2742_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrd2742/MediaObjects/41573_2009_Article_BFnrd2742_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrd2742/MediaObjects/41573_2009_Article_BFnrd2742_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrd2742/MediaObjects/41573_2009_Article_BFnrd2742_Fig4_HTML.jpg
         isPartOf:
            name:Nature Reviews Drug Discovery
            issn:
               1474-1784
               1474-1776
            volumeNumber:8
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Kathryn A. Whitehead
               affiliation:
                     name:Massachusetts Institute of Technology
                     address:
                        name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Robert Langer
               affiliation:
                     name:Massachusetts Institute of Technology
                     address:
                        name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
                        type:PostalAddress
                     type:Organization
                     name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology
                     address:
                        name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Daniel G. Anderson
               affiliation:
                     name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology
                     address:
                        name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Knocking down barriers: advances in siRNA delivery
      description: RNA interference holds vast potential as a therapeutic strategy for both disease prevention and treatment, but its use has so far been hampered by a lack of safe and effective delivery techniques. In their Review, Anderson and colleagues discuss the challenges associated with small interfering RNA delivery and highlight promising novel synthetic delivery agents. In the 10 years that have passed since the Nobel prize-winning discovery of RNA interference (RNAi), billions of dollars have been invested in the therapeutic application of gene silencing in humans. Today, there are promising data from ongoing clinical trials for the treatment of age-related macular degeneration and respiratory syncytial virus. Despite these early successes, however, the widespread use of RNAi therapeutics for disease prevention and treatment requires the development of clinically suitable, safe and effective drug delivery vehicles. Here, we provide an update on the progress of RNAi therapeutics and highlight novel synthetic materials for the encapsulation and intracellular delivery of nucleic acids.
      datePublished:
      dateModified:
      pageStart:129
      pageEnd:138
      sameAs:https://doi.org/10.1038/nrd2742
      keywords:
         Biomedicine
         general
         Pharmacology/Toxicology
         Biotechnology
         Medicinal Chemistry
         Molecular Medicine
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrd2742/MediaObjects/41573_2009_Article_BFnrd2742_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrd2742/MediaObjects/41573_2009_Article_BFnrd2742_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrd2742/MediaObjects/41573_2009_Article_BFnrd2742_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrd2742/MediaObjects/41573_2009_Article_BFnrd2742_Fig4_HTML.jpg
      isPartOf:
         name:Nature Reviews Drug Discovery
         issn:
            1474-1784
            1474-1776
         volumeNumber:8
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Kathryn A. Whitehead
            affiliation:
                  name:Massachusetts Institute of Technology
                  address:
                     name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Robert Langer
            affiliation:
                  name:Massachusetts Institute of Technology
                  address:
                     name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
                     type:PostalAddress
                  type:Organization
                  name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology
                  address:
                     name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Daniel G. Anderson
            affiliation:
                  name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology
                  address:
                     name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature Reviews Drug Discovery
      issn:
         1474-1784
         1474-1776
      volumeNumber:8
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Massachusetts Institute of Technology
      address:
         name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
         type:PostalAddress
      name:Massachusetts Institute of Technology
      address:
         name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
         type:PostalAddress
      name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology
      address:
         name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
         type:PostalAddress
      name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology
      address:
         name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Kathryn A. Whitehead
      affiliation:
            name:Massachusetts Institute of Technology
            address:
               name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
               type:PostalAddress
            type:Organization
      name:Robert Langer
      affiliation:
            name:Massachusetts Institute of Technology
            address:
               name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
               type:PostalAddress
            type:Organization
            name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology
            address:
               name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
               type:PostalAddress
            type:Organization
      name:Daniel G. Anderson
      affiliation:
            name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology
            address:
               name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
      name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
      name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
      name:The David H. Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(2)

External Links {🔗}(429)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Particles.js
Prism.js
Zoom.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

4.3s.